<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Marksans Pharma Limited — News on 6ix</title>
<link>https://6ix.com/company/marksans-pharma-limited</link>
<description>Latest news and press releases for Marksans Pharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 16:17:44 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/marksans-pharma-limited" rel="self" type="application/rss+xml" />
<item>
<title>Press Release Apr 01 2026</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-apr-01-2026-12</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-apr-01-2026-12</guid>
<pubDate>Wed, 01 Apr 2026 16:17:44 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)".</description>
</item>
<item>
<title>Press Release Feb 05 2026</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-feb-05-2026-46</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-feb-05-2026-46</guid>
<pubDate>Thu, 05 Feb 2026 19:05:29 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "unaudited financial results for Q3 FY26".</description>
</item>
<item>
<title>Press Release Nov 20 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-20-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-20-2025-12</guid>
<pubDate>Thu, 20 Nov 2025 18:12:28 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated November 20, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its product Cetirizine Dihydrochloride 1 mg/ml oral solution".</description>
</item>
<item>
<title>Press Release Nov 19 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-19-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-19-2025-12</guid>
<pubDate>Wed, 19 Nov 2025 16:23:49 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated November 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC)".</description>
</item>
<item>
<title>Press Release Nov 17 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-17-2025-17</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-17-2025-17</guid>
<pubDate>Mon, 17 Nov 2025 16:27:40 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its Products from UK MHRA.".</description>
</item>
<item>
<title>Press Release Nov 13 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-13-2025-50</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-13-2025-50</guid>
<pubDate>Fri, 14 Nov 2025 01:08:44 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Marksans Pharma Limited Press Release regarding unaudited financial results for the quarter and half year ended September 30, 2025".</description>
</item>
<item>
<title>Press Release Nov 10 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-10-2025-30</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-10-2025-30</guid>
<pubDate>Mon, 10 Nov 2025 17:19:24 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated November 10, 2025, titled " US FDA cGMP inspection at Company s 2nd manufacturing facility located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, India concluded with zero Form 483 observation.".</description>
</item>
<item>
<title>Press Release Nov 05 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-05-2025-31</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-nov-05-2025-31</guid>
<pubDate>Wed, 05 Nov 2025 14:18:09 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its product Exemestane 25mg film-coated tablet.".</description>
</item>
<item>
<title>Press Release Oct 15 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-oct-15-2025-25</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-oct-15-2025-25</guid>
<pubDate>Wed, 15 Oct 2025 18:06:43 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated October 15, 2025, titled "Marksans Pharma Ltd's wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA".</description>
</item>
<item>
<title>Press Release Sep 23 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-sep-23-2025-15</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-sep-23-2025-15</guid>
<pubDate>Tue, 23 Sep 2025 18:19:00 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated September 23, 2025, titled "Marksans Pharma Ltd's subsidiary Relonchem Limited in UK received marketing authorisation for its products from UK MHRA.".</description>
</item>
<item>
<title>Press Release Aug 18 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-aug-18-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-aug-18-2025-11</guid>
<pubDate>Mon, 18 Aug 2025 16:24:49 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated August 18, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for its products.".</description>
</item>
<item>
<title>Press Release Aug 12 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-aug-12-2025-45</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-aug-12-2025-45</guid>
<pubDate>Tue, 12 Aug 2025 17:29:18 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated August 12, 2025, titled "Q1FY26 Financial Results Marksans Pharma &#8377;620 Cr Revenue in Q1 FY26, up 5% YoY; Strong Cash Position of &#8377;711 Cr Supports Growth Initiatives".</description>
</item>
<item>
<title>Press Release Aug 08 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-aug-08-2025-33</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-aug-08-2025-33</guid>
<pubDate>Fri, 08 Aug 2025 14:48:08 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated August 08, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary Marksans Pharma Inc. receives USFDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC).".</description>
</item>
<item>
<title>Press Release Jun 30 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-jun-30-2025-18</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-jun-30-2025-18</guid>
<pubDate>Mon, 30 Jun 2025 17:17:22 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 30, 2025, titled "Receipt of EIR from USFDA for inspection conducted at manufacturing facility of Company s subsidiary Time-Cap Laboratories, Inc.".</description>
</item>
<item>
<title>Press Release Jun 19 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-jun-19-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-jun-19-2025-10</guid>
<pubDate>Thu, 19 Jun 2025 13:22:56 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated Jun 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in the UK, Relonchem Limited receives Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution.".</description>
</item>
<item>
<title>Press Release May 30 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-may-30-2025-23</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-may-30-2025-23</guid>
<pubDate>Fri, 30 May 2025 13:15:14 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated May 30, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for the product Metformin Hydrochloride 500 mg/ 5ml Oral Solution.".</description>
</item>
<item>
<title>Press Release May 19 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-may-19-2025-22</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-may-19-2025-22</guid>
<pubDate>Tue, 20 May 2025 00:50:38 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated May 19, 2025, titled "Press Release dated 19 May 2025 regarding audited financial results for the quarter and year ended 31 March 2025".</description>
</item>
<item>
<title>Press Release May 15 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-may-15-2025-36</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-may-15-2025-36</guid>
<pubDate>Thu, 15 May 2025 13:24:34 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution".</description>
</item>
<item>
<title>Press Release Apr 28 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-apr-28-2025-26</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-apr-28-2025-26</guid>
<pubDate>Mon, 28 Apr 2025 15:00:06 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated April 28, 2025, titled "USFDA inspection at manufacturing facility of Company s subsidiary Time-Cap Laboratories, Inc.".</description>
</item>
<item>
<title>Press Release Mar 20 2025</title>
<link>https://6ix.com/company/marksans-pharma-limited/news/press-release-mar-20-2025-18</link>
<guid isPermaLink="true">https://6ix.com/company/marksans-pharma-limited/news/press-release-mar-20-2025-18</guid>
<pubDate>Thu, 20 Mar 2025 15:27:01 GMT</pubDate>
<description>Marksans Pharma Limited has informed the Exchange regarding a press release dated March 20, 2025, titled "Marksans Pharma Limited s manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, has been approved by Australian TGA for manufacture of pharmaceutical formulations for Australian markets.".</description>
</item>
</channel>
</rss>